[go: up one dir, main page]

WO2010057503A2 - Long acting conserved natural functional groups curcumin - Google Patents

Long acting conserved natural functional groups curcumin Download PDF

Info

Publication number
WO2010057503A2
WO2010057503A2 PCT/EG2008/000044 EG2008000044W WO2010057503A2 WO 2010057503 A2 WO2010057503 A2 WO 2010057503A2 EG 2008000044 W EG2008000044 W EG 2008000044W WO 2010057503 A2 WO2010057503 A2 WO 2010057503A2
Authority
WO
WIPO (PCT)
Prior art keywords
curcumin
natural
novel
conserved
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EG2008/000044
Other languages
French (fr)
Other versions
WO2010057503A3 (en
Inventor
El-Sayed Ameen Mahmoud Rezq
Mohammad Talaat Abdel-Aziz Mansour
Taha Abdullah Kumosani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/EG2008/000044 priority Critical patent/WO2010057503A2/en
Priority to EP08878223A priority patent/EP2365956A4/en
Publication of WO2010057503A2 publication Critical patent/WO2010057503A2/en
Publication of WO2010057503A3 publication Critical patent/WO2010057503A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/08Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene

Definitions

  • This invention relates to the synthesis of a novel curcumin-protein conjugate with conserved natural functional groups necessary for curcumin biochemical, physiological and pharmacological functionality. It also relates to the novel intermediate essential for the synthesis of the abovementioned curcumin-protein conjugate.
  • novel derivatives relate to conveying lacking essential properties on natural curcumin such as; free water solubility, easy digestibility, free intestinal absorption, long serum half-life and improved original biochemical, physiological and pharmacological potencies of natural curcumin towards certain pre-studied effects in humans and experimental animal models.
  • Curcumin, l,7-Bis(4-hydroxy-3-methoxyphenyl)-l,6-heptadiene-3,5-dione is a component of turmeric, a yellow spice from the rhizome of the herb Curcuma longa L. (Zingiberaceae), that is widely used as a food flavoring and coloring agent.
  • Curcumin has a long history of medicinal use for a wide variety of medical conditions. It is insoluble in water but soluble in ethanol, alkalis, glacial acetic acid and chloroform.
  • additives as Piperine, (from black pepper), Quercetin (from various plants), Genistein (from soy) were used with the aim to inhibit the natural pumps that expel curcumin out of the intestinal and/or other cells.
  • Microemulsions e.g. natural oils such as peppermint oil, different surfactants such as lecithin, monoolein, Tween-20 were used with the aim to facilitate intestinal curcumin absorption in larger amounts.
  • Chemical derivatives e.g., tetrahydro curcumin, demethoxy curcumin, tetrahydrodemethoxy curcumin, bisdemethoxy curcumin, tetrahydro bisdemethoxy curcumin, hexahydrocurcumin, acetate, phosphate, gluconate, ..., etc. were used with the aim to avoid the abovementioned action of the intestinal enzymes/pumps and liver enzymes. But all such chemical derivatives were made through the use of the curcumin natural functional groups required for full biological activity, (biochemical, physiological and pharmacological potencies).
  • curcumin Long acting, conserved natural functional group curcumin, of free water solubility, easy digestibility, free intestinal absorption, long serum half-life should help getting the utmost possible beneficial effects of this historical, albeit promising treatment of several acute and chronic illnesses.
  • Nitrous acid was generated by the addition of a solution of 0.85 niEq of sodium nitrite to an excess of HCl. The reaction was maintained at a temperature of 5°C. A solution of 0.85 niEq of 4-aniinobenzoic acid in IN HCl chilled to 5 0 C was prepared with continuous stirring in ice bath for 20 minutes, the pH of 1.0 was never exceeded. Diazotized 4-minobenzoic acid was added dropwise to an equivalent concentration, (0.85 mEq) of curcumin, (I) dissolved in ethanol at pH 11.0 with continuous stirring at 5 0 C.
  • the curcumin-bovine serum albumin conjugate (III), of this invention was synthesized in a medium of 1% NaCl/dioxane/NaOH solution of pH 8-10, at 5 0 C, by adding 0.1M solution of l-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate to purified crystalline l,7-bis(5-carboxyphenylazo-4-hydroxy-3- methoxyphenyl)-l,6-heptadiene-3,5-dione, (II) in the same medium with continuous stirring.
  • Bovine serum albumin was added to the foregoing mixture at 5 0 C, pH 8-10 with continuous stirring for 1 hr until the intermediate azopseudourea has conjugated to bovine serum albumin, after which the mixture was centrifuged off, acidified to pH 4.2, salted out, recentrifuged, redissolved then dialyzed for 24 hr at 5 0 C against 0.5M sodium carbonate, pH 8.2 until any color no longer appears in dialysis solution. A final dialysis is performed against bi-distilled water for 24 hours at 5°C, after which the protein conjugate (III) was lyophilized.
  • novel curcumin derivatives (II) and (III) were characterized by IR Spectroscopy, GC/MS, NMR, EM, TLC, Gel Filtration, Continuous Flow Electrophoresis and Isoelectric Focusing whenever applicable.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Curcumin is a component of turmeric, a yellow spice from the rhizome of the herb Curcuma longa L. (Zingiberaceae), that is widely used as a food flavoring and coloring agent. Curcumin has a long history of medicinal use for a wide variety of medical conditions. It is insoluble in water but soluble in ethanol, alkalis, glacial acetic acid and chloroform. Oral administration is well tolerated, but bioavailability is very low. Long acting, conserved natural functional group curcumin, of free water solubility, easy digestibility, free intestinal absorption, long serum half-life should help getting the utmost possible beneficial effects of this historical, albeit promising treatment of several acute and chronic illnesses. Natural pure water insoluble curcumin has been converted to a novel, water soluble conserved natural functional group derivatives, with no change to its original active functional natural molecular chemical groups necessary for full biochemical, physiological and pharmacological potencies previously reported for natural curcumin. The novel curcumin derivatives were characterized by IR Spectroscopy, GC/MS, NMR, EM, TLC, Gel Filtration, Continuous Flow Electrophoresis and Isoelectric Focusing whenever applicable. Laboratory animal studies of the novel curcumin derivatives proved that they conserved all the natural curcumin functionality in addition to the novel free water solubility, easy digestibility, free intestinal absorption, long serum half-life besides improved original biochemical, physiological and pharmacological potencies of natural curcumin towards certain pre-studied effects in humans and experimental animal models e.g. erectile dysfunction, diabetes mellitus.

Description

LONG ACTING CONSERVED NATURAL FUNCTIONAL GROUPS CURCUMIN
Technical Field
This invention relates to the synthesis of a novel curcumin-protein conjugate with conserved natural functional groups necessary for curcumin biochemical, physiological and pharmacological functionality. It also relates to the novel intermediate essential for the synthesis of the abovementioned curcumin-protein conjugate.
In addition, the novel derivatives relate to conveying lacking essential properties on natural curcumin such as; free water solubility, easy digestibility, free intestinal absorption, long serum half-life and improved original biochemical, physiological and pharmacological potencies of natural curcumin towards certain pre-studied effects in humans and experimental animal models.
Such novel derivatives with their improved properties are intended to be used in medical studies in experimental animal models to try to get better medicinal effects that were not achievable with natural curcumin.
Background Art
Curcumin, l,7-Bis(4-hydroxy-3-methoxyphenyl)-l,6-heptadiene-3,5-dione is a component of turmeric, a yellow spice from the rhizome of the herb Curcuma longa L. (Zingiberaceae), that is widely used as a food flavoring and coloring agent. Curcumin has a long history of medicinal use for a wide variety of medical conditions. It is insoluble in water but soluble in ethanol, alkalis, glacial acetic acid and chloroform.
Oral administration is well tolerated, but bioavailability is very low. However, when curcumin is used as a supplement, it is absorbed quickly but does not stay in the body for long. The cells lining of the intestine are equipped with enzymes that convert curcumin into other substances, and also with molecular pumps that pump curcumin and its byproducts out of the intestinal lining back into the intestine. Less than 1% of the curcumin actually makes its way to the bloodstream, where the liver rapidly destroys most of it. To counteract this problem, Bioperine which is a unique blend from black and long pepper was used as an additive. It enhances the absorption of curcumin in the body. But for people who have medical conditions, or who are taking other supplements or drugs, all kinds of risks are elevated as such substances are known to interact with various drugs used to treat several medical conditions.
In general three different approaches were used to improve cuecumin bioavailability; namely: additives, microemulsions and chemical derivatives, but none proved to overcome the problem. Additives as Piperine, (from black pepper), Quercetin (from various plants), Genistein (from soy) were used with the aim to inhibit the natural pumps that expel curcumin out of the intestinal and/or other cells. Microemulsions, e.g. natural oils such as peppermint oil, different surfactants such as lecithin, monoolein, Tween-20 were used with the aim to facilitate intestinal curcumin absorption in larger amounts. Chemical derivatives e.g., tetrahydro curcumin, demethoxy curcumin, tetrahydrodemethoxy curcumin, bisdemethoxy curcumin, tetrahydro bisdemethoxy curcumin, hexahydrocurcumin, acetate, phosphate, gluconate, ..., etc. were used with the aim to avoid the abovementioned action of the intestinal enzymes/pumps and liver enzymes. But all such chemical derivatives were made through the use of the curcumin natural functional groups required for full biological activity, (biochemical, physiological and pharmacological potencies).
Long acting, conserved natural functional group curcumin, of free water solubility, easy digestibility, free intestinal absorption, long serum half-life should help getting the utmost possible beneficial effects of this historical, albeit promising treatment of several acute and chronic illnesses.
Disclosure of Invention
Curcumin, l,7-bis(4-hydroxy-3-methoxyphenyl)-l,6-heptadiene-3,5-dione (I), was coupled to diazotized 4-aminobenzoic acid for the synthesis of the novel compound 1 ,7-bis(5-carboxyphenylazo-4-hydroxy-3 -methoxyphenyl)- 1 ,6-heptadiene-3 ,5 -dione (II), which in turn was utilized for the synthesis of the novel curcumin-bovine serum albumin conjugate (III), through the use of l-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate. Both compounds (II) and (III) represent the novel embodiment of this invention. ^
Nitrous acid was generated by the addition of a solution of 0.85 niEq of sodium nitrite to an excess of HCl. The reaction was maintained at a temperature of 5°C. A solution of 0.85 niEq of 4-aniinobenzoic acid in IN HCl chilled to 50C was prepared with continuous stirring in ice bath for 20 minutes, the pH of 1.0 was never exceeded. Diazotized 4-minobenzoic acid was added dropwise to an equivalent concentration, (0.85 mEq) of curcumin, (I) dissolved in ethanol at pH 11.0 with continuous stirring at 50C. The solution was acidified to pH 2.0 at which derivative (II) l,7-bis(5- carboxyphenylazo-4-hydroxy-3 -methoxyphenyl)- 1 ,6-heptadiene-3 ,5 -dione was precipitated. The precipitate was centrifuged and redissolved in ethanol at pH 11.0 again. After repeating the acid and base cycle twice, the crude derivative (II) was chromatographed on a column of silica gel. Reduced pressure evaporation of the elution solvent gave a derivative of about 98% purity as checked by TLC. The curcumin-bovine serum albumin conjugate (III), of this invention was synthesized in a medium of 1% NaCl/dioxane/NaOH solution of pH 8-10, at 50C, by adding 0.1M solution of l-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate to purified crystalline l,7-bis(5-carboxyphenylazo-4-hydroxy-3- methoxyphenyl)-l,6-heptadiene-3,5-dione, (II) in the same medium with continuous stirring. Bovine serum albumin was added to the foregoing mixture at 50C, pH 8-10 with continuous stirring for 1 hr until the intermediate azopseudourea has conjugated to bovine serum albumin, after which the mixture was centrifuged off, acidified to pH 4.2, salted out, recentrifuged, redissolved then dialyzed for 24 hr at 50C against 0.5M sodium carbonate, pH 8.2 until any color no longer appears in dialysis solution. A final dialysis is performed against bi-distilled water for 24 hours at 5°C, after which the protein conjugate (III) was lyophilized. The novel curcumin derivatives (II) and (III) were characterized by IR Spectroscopy, GC/MS, NMR, EM, TLC, Gel Filtration, Continuous Flow Electrophoresis and Isoelectric Focusing whenever applicable.

Claims

Claims
We claim; the synthesis of long acting, conserved natural functional group curcumin derivatives, of. free water solubility, easy digestibility, free intestinal absorption, higher bioavailability and longer serum half-life for the utmost possible beneficial effects in treatment of several previously reported acute and chronic illnesses treated with curcumin.
This invention relates specifically to the synthesis of a novel conserved natural functional group curcumin-protein conjugate, conserving the essential original biochemical, physiological and pharmacological potencies of natural curcumin towards certain pre-studied effects in humans and experimental animal models.
The invention also relates to a novel intermediate essential for the preparation of the abovementioned compound as well as the use of the claimed derivatives in medical studies in experimental animals for treatment from some acute and chronic illnesses e.g. erectile dysfunction, diabetes mellitus and all other illnesses reported to be treated or benefited from natural curcumin treatment.
Natural pure water insoluble curcumin has been converted to a novel, water soluble conserved natural functional group derivatives, with no change to its original active functional natural molecular chemical groups necessary for full biochemical, physiological and pharmacological potencies previously reported for natural curcumin. The novel curcumin derivatives were characterized by IR Spectroscopy, GC/MS, NMR, EM, TLC, Gel Filtration, Continuous Flow Electrophoresis and Isoelectric Focusing whenever applicable.
Laboratory animal studies of the novel curcumin derivatives proved that they conserved all the natural curcumin functionality in addition to the novel free water solubility, easy digestibility, free intestinal absorption, long serum half-life besides improved original biochemical, physiological and pharmacological potencies of natural curcumin towards certain pre-studied effects in humans and experimental animal models e.g. erectile dysfunction, diabetes mellitus.
PCT/EG2008/000044 2008-11-20 2008-11-20 Long acting conserved natural functional groups curcumin Ceased WO2010057503A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/EG2008/000044 WO2010057503A2 (en) 2008-11-20 2008-11-20 Long acting conserved natural functional groups curcumin
EP08878223A EP2365956A4 (en) 2008-11-20 2008-11-20 Long acting conserved natural functional groups curcumin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EG2008/000044 WO2010057503A2 (en) 2008-11-20 2008-11-20 Long acting conserved natural functional groups curcumin

Publications (2)

Publication Number Publication Date
WO2010057503A2 true WO2010057503A2 (en) 2010-05-27
WO2010057503A3 WO2010057503A3 (en) 2010-07-15

Family

ID=42198568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2008/000044 Ceased WO2010057503A2 (en) 2008-11-20 2008-11-20 Long acting conserved natural functional groups curcumin

Country Status (2)

Country Link
EP (1) EP2365956A4 (en)
WO (1) WO2010057503A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014192024A1 (en) * 2013-05-20 2014-12-04 Sree Chitra Tirunal Institute For Medical Sciences And Technology Development of soluble albuminated curcumin for application in cancer therapy
WO2016025541A1 (en) * 2014-08-12 2016-02-18 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en) * 2016-11-30 2018-06-07 Wang tian xin Therapeutical methods, formulations and nutraceutical formulations
US10561650B2 (en) 2013-03-14 2020-02-18 Christopher Brian Reid Method for treating a protozoal infection
US10576117B2 (en) * 2017-04-24 2020-03-03 Muniyal Ayurvedic Research Centre Herbo-mineral formulation for prevention, treatment and management of diabetes and method of preparation thereof
CN112245414A (en) * 2020-10-15 2021-01-22 四川大学华西医院 Application of curcumin or its drug-carrying system in preparation of drugs for treating penile erectile dysfunction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None
See also references of EP2365956A2

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561650B2 (en) 2013-03-14 2020-02-18 Christopher Brian Reid Method for treating a protozoal infection
WO2014192024A1 (en) * 2013-05-20 2014-12-04 Sree Chitra Tirunal Institute For Medical Sciences And Technology Development of soluble albuminated curcumin for application in cancer therapy
US10849983B2 (en) 2013-05-20 2020-12-01 Sree Chitra Tirunal Institute For Medical Sciences And Technology Development of soluble albuminated curcumin for application in cancer therapy
WO2016025541A1 (en) * 2014-08-12 2016-02-18 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en) * 2016-11-30 2018-06-07 Wang tian xin Therapeutical methods, formulations and nutraceutical formulations
US10576117B2 (en) * 2017-04-24 2020-03-03 Muniyal Ayurvedic Research Centre Herbo-mineral formulation for prevention, treatment and management of diabetes and method of preparation thereof
US10639341B2 (en) 2017-04-24 2020-05-05 Muniyal Ayurvedic Research Centre Herbo-mineral formulation for prevention, treatment and management of diabetes and method of preparation thereof
CN112245414A (en) * 2020-10-15 2021-01-22 四川大学华西医院 Application of curcumin or its drug-carrying system in preparation of drugs for treating penile erectile dysfunction

Also Published As

Publication number Publication date
EP2365956A4 (en) 2012-07-25
EP2365956A2 (en) 2011-09-21
WO2010057503A3 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
WO2010057503A2 (en) Long acting conserved natural functional groups curcumin
CN102802636A (en) Hydrolysate of crocin
FI74290C (en) FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA S-ADENOCYLMETIONINDERIVAT.
US20210008088A1 (en) Composition for preventing or treating non-alcoholic liver disease or insulin resistance comprising ginsenoside f2
CN117222432A (en) Polyphenol composition with improved bioavailability
JP5459826B2 (en) Elastin production promoter and vascular endothelial cell growth promoter in dermal fibroblasts
TWI564291B (en) Agent for regulating the formation of nitrogen monoxide
CN109456395A (en) A kind of incretin peptide and its application
WO2011100984A1 (en) Gelatin, a curcumin drug carrier system
KR20140106772A (en) Composition for inhibition of gout comprising extracts of chrysanthemum indicum L.
JP3543175B2 (en) α-glucosidase inhibitor
SE457958B (en) WATER-SOLUBLE HEMIN ARGINATE OR HEMIN-LYSINATE SOCIETY, PROCEDURE FOR PREPARING THEREOF AND USING THEREOF FOR MANUFACTURE OF MEDICAL COMPOSITIONS
JPH07223940A (en) Active oxygen eliminating agent and composition containing the same
DE60308994T2 (en) PROCESS FOR EXTRACTION, CLEANING AND ENZYMATIC CHANGING OF SOYA 7S GLOBULIN ALPHA &#39;SUBMERCH FOR USE AS HYPOCHOLESTEROL MIXER ACTIVE
JP6873904B2 (en) Xanthine oxidase inhibitor
RU2366408C1 (en) Gel composition of wound healing, burntreating, antiinflammatory, hepatoprotective, antidiabetic and antineoplastic action
JP2944345B2 (en) Anti-inflammatory, anti-itch external preparation
CN113209062A (en) Study on carp liver injury protection effect of curcumin through activation of activity of Nrf2
KR100414187B1 (en) Hepatoprotective extract derived from Protaetia brevitarsis and its use
CN114652850B (en) Polypeptide coupled NMN compound with anti-aging effect and application thereof
KR100210414B1 (en) Amino acid containing polysaccharide of artemisia iwayomigi and its purification method
WO2017036528A1 (en) Cyanobacterial microalgae, phycocyanin and phycocyanobilin to beneficially inhibit the activity of the udp-gdh enzyme while significantly increasing the absorption and circulation of curcumin
RU2177321C1 (en) Selenium-containing carotene-protein organic substance for regulation of metabolic processes (its variants)
CN115671254A (en) A kind of Antarctic krill peptide-polyphenol compound and its application
KR102079065B1 (en) Pharmaceutical composition comprising dehydro-6-gingerdione for prevention or treatment of metabolic disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08878223

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2008878223

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008878223

Country of ref document: EP